GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Q32 Bio Inc (NAS:QTTB) » Definitions » Debt-to-Revenue

Q32 Bio (Q32 Bio) Debt-to-Revenue : N/A (As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Q32 Bio Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Q32 Bio's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $4.65 Mil. Q32 Bio's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $15.50 Mil. Q32 Bio's annualized Revenue for the quarter that ended in Mar. 2024 was $0.00 Mil.

Q32 Bio Debt-to-Revenue Historical Data

The historical data trend for Q32 Bio's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Q32 Bio Debt-to-Revenue Chart

Q32 Bio Annual Data
Trend Dec21 Dec22 Dec23
Debt-to-Revenue
N/A 6.73 N/A

Q32 Bio Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Debt-to-Revenue Get a 7-Day Free Trial 2.96 - N/A N/A N/A

Competitive Comparison of Q32 Bio's Debt-to-Revenue

For the Biotechnology subindustry, Q32 Bio's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Q32 Bio's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Q32 Bio's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Q32 Bio's Debt-to-Revenue falls into.


Q32 Bio Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Q32 Bio's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(1.416 + 49.424) / -6.651
=-7.64

Q32 Bio's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(4.648 + 15.499) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2024) Revenue data.

Q32 Bio Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Q32 Bio's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Q32 Bio (Q32 Bio) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Q32 Bio Inc (NAS:QTTB) » Definitions » Debt-to-Revenue
Comparable Companies
Traded in Other Exchanges
N/A
Address
830 Winter Street, Waltham, MA, USA, 02451
Website
https://www.q32bio.com
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.

Q32 Bio (Q32 Bio) Headlines

From GuruFocus

Q32 Bio Appoints Lee Kalowski as President & Chief Financial Officer

By PRNewswire • 04-03-2024